Iterum Therapeutics plc (ITRM)

1.1000 +0.0100 (+0.92%) As of 11:01AM EDT. Market open.

Iterum Therapeutics plc

Fitzwilliam Court
1st Floor Leeson Close
Dublin D02 YW24
Ireland
353 1 669 4820
https://www.iterumtx.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 14

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Corey N. Fishman	President, CEO & Director	1.3M	N/A	1965
Ms. Judith M. Matthews	Chief Financial Officer	747.77k	N/A	1970
Dr. Michael W. Dunne M.D.	Strategic Advisor & Director	115k	N/A	1960
Mr. Tom Loughman Ph.D.	Senior Vice President of Technical Operations	N/A	N/A	N/A
Ms. Louise Barrett	Senior Vice President of Legal Affairs & Secretary	N/A	N/A	N/A
Dr. Steven I. Aronin M.D.	Senior VP & Head of Clinical Development	N/A	N/A	N/A

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

Corporate Governance

Iterum Therapeutics plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.